Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: Analysis from the treatment approaches in renal cancer global evaluation trial (TARGET)

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 8, 2013, Pages 1788-1793

  Choueiri, Toni K ^a,b,c   Cheng, Suchun ^a   Qu, Angela Q ^b   Pastorek, Jaromir ^d   Atkins, Michael B ^a,e   Signoretti, Sabina ^a,b,c  

^a DANA FARBER HARVARD CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d INSTITUTE OF VIROLOGY   (Slovakia)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Biomarker; Carbonic anhydrase IX; Prognostic marker; Renal cell carcinoma (RCC); Sorafenib; Vascular endothelial growth factor

Indexed keywords

BIOLOGICAL MARKER; CARBONATE DEHYDRATASE IX; PARAFFIN; PLACEBO; SORAFENIB;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR VOLUME;

BIOMARKER; CARBONIC ANHYDRASE IX; PROGNOSTIC MARKER; RENAL CELL CARCINOMA (RCC); SORAFENIB; VASCULAR ENDOTHELIAL GROWTH FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84886245708     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2012.07.004     Document Type: Article

References (19)

1. Choueiri T.K., Regan M.M., Rosenberg J.E., et al. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. BJU Int 2010, 106:772-778.
2. Motzer R.J., Bacik J., Mazumdar M. Prognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial Sloan-Kettering Cancer Center experience. Clin Cancer Res 2004, 10:6302S-6303S.
3. Appleby L., Morrissey S., Bellmunt J., et al. Management of treatment-related toxicity with targeted therapies for renal cell carcinoma: Evidence-based practice and best practices. Hematol Oncol Clin North Am 2011, 25:893-915.
4. Choueiri T.K., Bukowski R.M., Rini B.I. The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma. Semin Oncol 2006, 33:596-606.
5. Di Napoli A, Grisanzio C, Ghebremichael M, et al. CAIX expression correlates with VHL mutational status in sporadic clear cell carcinoma of the kidney. Proceedings of the Annual Meeting, United States and Canadian Division of the International Academy of Pathology; Denver CO, 2008.
6. Dorai T., Sawczuk I.S., Pastorek J., et al. The role of carbonic anhydrase IX overexpression in kidney cancer. Eur J Cancer 2005, 41:2935-2947.
7. Bui M.H., Seligson D., Han K.R., et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: Implications for prognosis and therapy. Clin Cancer Res 2003, 9:802-811.
8. Atkins M., Regan M., McDermott D., et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005, 11:3714-3721.
9. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
10. Courtney K.D., Choueiri T.K. Updates on novel therapies for metastatic renal cell carcinoma. Ther adv. Med Oncol 2010, 2:209-219.
11. Molina A.M., Motzer R.J. Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: Today and tomorrow. Oncologist 2011, 16(Suppl 2):45-50.
12. Choueiri T.K., Vaziri S.A., Jaeger E., et al. Von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol 2008, 180:860-865. Discussion:5-6.
13. Johnson J.R., Williams G., Pazdur R. End points and united states food and drug administration approval of oncology drugs. J Clin Oncol 2003, 21:1404-1411.
14. Heng D.Y., Xie W., Bjarnason G.A., et al. Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. Cancer 2011, 117:2637-2642.
15. Peña C., Lathia C., Shan M., et al. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III treatment approaches in renal cancer global evaluation trial. Clin Cancer Res 2010, 16:4853-4863.
16. Tran H.T., Lui Y., Zurita A.J., et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: A retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol 2012, 13:827-837.
17. Pantuck A.J., Klatte T., Seligson D., et al. Carbonic anhydrase IX as a predictive biomarker for clear cell renal cell carcinoma. J Clin Oncol 2008, 26:3105-3107. Author reply:7-9.
18. Leibovich B.C., Sheinin Y., Lohse C.M., et al. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol 2007, 25:4757-4764.
19. Bahamon B., Signoretti S. Tissue biomarkers in renal cell carcinoma: Intermediate endpoints in the selection of targeted agents for RCC. Renal cell carcinoma: Biology, prognostic factors and therapeutic targets 2012, Springer, New York, NY. K. Rathmell, B. Rini, R.A. Figlin (Eds.).